Table 1 Clinical characteristic of Patients Enrolled in this Study

From: Liver transplant-facilitated CD161+Vα7.2+ MAIT cell recovery demonstrates clinical benefits in hepatic failure patients

 

blood

Nontumor Liver Specimens

samples

Comp

LF

HBVN

Comp

LF

NO.

180

107

50

70

42

Sex(M/F)

126/54

87/20

26/24

58/12

36/6

Age(year)*

47(36–58)

47(37–57)

49(35–63)

50(40–60)

46(36–56)

HBV-DNA, log10copies/mL#

2.7(2.7–3.94)

4.6(2.8–6.1)

ND

3.2(2.0–5.0)

5.3(2.6–6.8)

ALT(U/L)#

26(19–43)

70(36–244)

16(11–30)

27(18–42)

53(31–413)

AST(U/L)#

25(21–37)

95(50–246)

19.5(15–25)

28.5(22–42.2)

92(49.5–451.5)

BA(μmol/L)#

5.2(2.8–11.1)

179(151–279)

4.2(2.5–6.4)

4.0(2.5–7.8)

236(134–278)

TBIL(μmol/L)#

13.4(10.4–18.5)

290(164–432)

11.3(6.8–16.6)

13.2(8.9–18.8)

236(90–412)

  1. ND not determined. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Bile acid (BA), Total bilirubin (TBIL). Data are shown as mean (range)* or median (range)#
Back to article page